Klinikum der LMU Muenchen

München 81377

1 studies enrolling now · 6 studies all time

What they study most

Active Refractory Rheumatoid Arthritis, Choroidal Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Indeterminate Lesions, Metastatic Colorectal Cancer, Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL), Non-Small Cell Lung Cancer (NSCLC), Ocular Melanoma, Systemic Lupus Erythematosus, Uveal Melanoma

Studies at this site

• A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases — Recruiting now
• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) — Recruiting now
• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation — Recruiting now
• A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma — Running, not enrolling
• Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. — Stopped early
• Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia — Running, not enrolling